Wellington Management Group LLP Takes $675,000 Position in Aldeyra Therapeutics, Inc. $ALDX

Wellington Management Group LLP bought a new stake in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 117,475 shares of the biotechnology company’s stock, valued at approximately $675,000. Wellington Management Group LLP owned approximately 0.20% of Aldeyra Therapeutics at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Dimensional Fund Advisors LP boosted its holdings in shares of Aldeyra Therapeutics by 21.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 735,763 shares of the biotechnology company’s stock valued at $3,672,000 after buying an additional 131,722 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Aldeyra Therapeutics by 1,575.7% in the 1st quarter. Invesco Ltd. now owns 501,137 shares of the biotechnology company’s stock valued at $2,882,000 after buying an additional 471,231 shares in the last quarter. Northern Trust Corp boosted its stake in Aldeyra Therapeutics by 4.3% during the 4th quarter. Northern Trust Corp now owns 405,517 shares of the biotechnology company’s stock worth $2,024,000 after purchasing an additional 16,894 shares during the period. Deutsche Bank AG boosted its stake in Aldeyra Therapeutics by 6.2% during the 4th quarter. Deutsche Bank AG now owns 319,287 shares of the biotechnology company’s stock worth $1,593,000 after purchasing an additional 18,696 shares during the period. Finally, Woodstock Corp boosted its stake in Aldeyra Therapeutics by 14.5% during the 1st quarter. Woodstock Corp now owns 223,094 shares of the biotechnology company’s stock worth $1,283,000 after purchasing an additional 28,175 shares during the period. Institutional investors and hedge funds own 59.71% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ALDX. Zacks Research upgraded shares of Aldeyra Therapeutics to a “hold” rating in a research note on Friday, August 8th. Wall Street Zen upgraded shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a research note on Monday, May 19th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Aldeyra Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $9.50.

Insider Buying and Selling

In related news, insider Stephen Machatha sold 22,073 shares of the stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $5.15, for a total value of $113,675.95. Following the sale, the insider directly owned 221,799 shares of the company’s stock, valued at approximately $1,142,264.85. This represents a 9.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 8.50% of the company’s stock.

Aldeyra Therapeutics Stock Performance

Shares of Aldeyra Therapeutics stock opened at $5.84 on Tuesday. The company has a market cap of $349.82 million, a P/E ratio of -6.87 and a beta of 0.80. Aldeyra Therapeutics, Inc. has a one year low of $1.14 and a one year high of $7.20. The firm has a fifty day moving average of $5.02 and a two-hundred day moving average of $4.23.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.05. As a group, equities analysts predict that Aldeyra Therapeutics, Inc. will post -0.92 earnings per share for the current year.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.